Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin versus furosemide for resistant hypertension with subclinical fluid retention in chronic kidney disease
ISRCTN14012970Phase 4Completed
- Sponsor
- Bhumibol Adulyadej Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin and furosemide in resistant hypertension (RH) and chronic kidney disease (CKD), sponsored by Bhumibol Adulyadej Hospital. Primary endpoint: Blood pressure. Started Jan 2024; status: completed.
02
Drugs
dapagliflozinfurosemide
03
Conditions
resistant hypertension (RH)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ISRCTN14012970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14012970.